125 related articles for article (PubMed ID: 30392324)
1. [Establishment and evaluation of a triple-color human papillomavirus pseudovirion neutralization assay].
Wei SP; Fan F; Chen J; Liu XL; Yang YR; Wang ZP; Song S; Li ZH; Wei MX; Wang DN; Li SW; Xia NS
Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Oct; 52(10):1039-1044. PubMed ID: 30392324
[No Abstract] [Full Text] [Related]
2. Development of a Triple-Color Pseudovirion-Based Assay to Detect Neutralizing Antibodies against Human Papillomavirus.
Nie J; Liu Y; Huang W; Wang Y
Viruses; 2016 Apr; 8(4):107. PubMed ID: 27120611
[TBL] [Abstract][Full Text] [Related]
3. Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination.
Zhao H; Lin ZJ; Huang SJ; Li J; Liu XH; Guo M; Zhang J; Xia NS; Pan HR; Wu T; Li CG
Hum Vaccin Immunother; 2014; 10(3):740-6. PubMed ID: 24384608
[TBL] [Abstract][Full Text] [Related]
4. Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.
Wang JW; Jagu S; Wang C; Kitchener HC; Daayana S; Stern PL; Pang S; Day PM; Huh WK; Roden RB
PLoS One; 2014; 9(7):e101576. PubMed ID: 24999962
[TBL] [Abstract][Full Text] [Related]
5. Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18.
Brown D; Müller M; Sehr P; Pawlita M; Seitz H; Rubio I; Antonello J; Radley D; Roberts C; Saah A
Vaccine; 2014 Oct; 32(44):5880-7. PubMed ID: 25148777
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of two different assay kits for the detection of secreted alkaline phosphatase in HPV antibody neutralization assays.
Kemp TJ; Matsui K; Shelton G; Safaeian M; Pinto LA
Hum Vaccin Immunother; 2015; 11(2):337-46. PubMed ID: 25695397
[TBL] [Abstract][Full Text] [Related]
7. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.
Pastrana DV; Buck CB; Pang YY; Thompson CD; Castle PE; FitzGerald PC; Krüger Kjaer S; Lowy DR; Schiller JT
Virology; 2004 Apr; 321(2):205-16. PubMed ID: 15051381
[TBL] [Abstract][Full Text] [Related]
8. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine.
Dessy FJ; Giannini SL; Bougelet CA; Kemp TJ; David MP; Poncelet SM; Pinto LA; Wettendorff MA
Hum Vaccin; 2008; 4(6):425-34. PubMed ID: 18948732
[TBL] [Abstract][Full Text] [Related]
9. High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses.
Sehr P; Rubio I; Seitz H; Putzker K; Ribeiro-Müller L; Pawlita M; Müller M
PLoS One; 2013; 8(10):e75677. PubMed ID: 24124504
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity correlation in cynomolgus monkeys between Luminex-based total IgG immunoassay and pseudovirion-based neutralization assay for a 14-valent recombinant human papillomavirus vaccine.
Bei L; Zhang X; Meng D; Gao S; Jia J; Zhao D; Luo C; Li X; Qiu H; Xie L
J Med Virol; 2022 Aug; 94(8):3946-3955. PubMed ID: 35388509
[TBL] [Abstract][Full Text] [Related]
11. A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies.
Day PM; Pang YY; Kines RC; Thompson CD; Lowy DR; Schiller JT
Clin Vaccine Immunol; 2012 Jul; 19(7):1075-82. PubMed ID: 22593236
[TBL] [Abstract][Full Text] [Related]
12. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trial.
Leung TF; Liu AP; Lim FS; Thollot F; Oh HML; Lee BW; Rombo L; Tan NC; Rouzier R; De Simoni S; Suryakiran P; Hezareh M; Thomas F; Folschweiller N; Struyf F
Vaccine; 2018 Jan; 36(1):98-106. PubMed ID: 29174109
[TBL] [Abstract][Full Text] [Related]
13. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination.
Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; de Borba PC; Sanchez N; Zahaf T; Catteau G; Geeraerts B; Descamps D
Hum Vaccin Immunother; 2014; 10(8):2147-62. PubMed ID: 25424918
[TBL] [Abstract][Full Text] [Related]
14. Production of Human papillomavirus pseudovirions in plants and their use in pseudovirion-based neutralisation assays in mammalian cells.
Lamprecht RL; Kennedy P; Huddy SM; Bethke S; Hendrikse M; Hitzeroth II; Rybicki EP
Sci Rep; 2016 Feb; 6():20431. PubMed ID: 26853456
[TBL] [Abstract][Full Text] [Related]
15. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial.
Einstein MH; Takacs P; Chatterjee A; Sperling RS; Chakhtoura N; Blatter MM; Lalezari J; David MP; Lin L; Struyf F; Dubin G;
Hum Vaccin Immunother; 2014; 10(12):3435-45. PubMed ID: 25483701
[TBL] [Abstract][Full Text] [Related]
16. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
[TBL] [Abstract][Full Text] [Related]
17. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial.
Krajden M; Cook D; Yu A; Chow R; Su Q; Mei W; McNeil S; Money D; Dionne M; Palefsky J; Karunakaran K; Kollmann T; Ogilvie G; Petric M; Dobson S
Vaccine; 2014 Jan; 32(5):624-30. PubMed ID: 24055350
[TBL] [Abstract][Full Text] [Related]
18. [The preliminary analysis on immunogenicity of DNA vaccines against human papillomavirus 58].
Wu XL; Nie JH; Zhang CT; Wu Y; Zhao CY; Wang YC
Bing Du Xue Bao; 2008 May; 24(3):196-201. PubMed ID: 18683556
[TBL] [Abstract][Full Text] [Related]
19. Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes.
Kalnin K; Tibbitts T; Yan Y; Stegalkina S; Shen L; Costa V; Sabharwal R; Anderson SF; Day PM; Christensen N; Schiller JT; Jagu S; Roden RB; Almond J; Kleanthous H
Vaccine; 2014 Jun; 32(28):3540-7. PubMed ID: 24780250
[TBL] [Abstract][Full Text] [Related]
20. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
